Mackenzie Financial Corp Decreases Stock Holdings in Accuray Incorporated (NASDAQ:ARAY)

Mackenzie Financial Corp lessened its stake in Accuray Incorporated (NASDAQ:ARAY) by 58.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,307 shares of the medical equipment provider’s stock after selling 31,032 shares during the period. Mackenzie Financial Corp’s holdings in Accuray were worth $41,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in shares of Accuray in the 2nd quarter worth approximately $910,000. Assenagon Asset Management S.A. purchased a new position in Accuray in the second quarter worth $132,000. Williams & Novak LLC increased its position in shares of Accuray by 259.2% during the second quarter. Williams & Novak LLC now owns 96,900 shares of the medical equipment provider’s stock worth $176,000 after purchasing an additional 69,925 shares in the last quarter. Perritt Capital Management Inc lifted its holdings in shares of Accuray by 139.3% during the 2nd quarter. Perritt Capital Management Inc now owns 120,000 shares of the medical equipment provider’s stock valued at $218,000 after purchasing an additional 69,864 shares during the last quarter. Finally, Heartland Advisors Inc. boosted its position in shares of Accuray by 2.2% in the 1st quarter. Heartland Advisors Inc. now owns 2,919,200 shares of the medical equipment provider’s stock worth $7,210,000 after purchasing an additional 61,700 shares in the last quarter. 64.08% of the stock is currently owned by institutional investors.

Accuray Trading Down 2.1 %

Shares of NASDAQ:ARAY opened at $1.84 on Wednesday. The business’s 50-day moving average is $1.92 and its 200 day moving average is $1.92. The company has a debt-to-equity ratio of 3.65, a current ratio of 1.66 and a quick ratio of 0.95. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $3.05. The firm has a market capitalization of $182.61 million, a P/E ratio of -8.36 and a beta of 1.39.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. The firm had revenue of $134.29 million for the quarter, compared to the consensus estimate of $122.80 million. Accuray had a negative net margin of 3.48% and a negative return on equity of 33.65%. During the same quarter in the prior year, the company posted ($0.03) earnings per share. On average, research analysts predict that Accuray Incorporated will post -0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.